Adverse reactions observed in KEYNOTE-407 were similar to those observed in KEYNOTE-189 with the exception that increased incidences of alopecia (47% vs 36%) and peripheral neuropathy (31% vs 25%) were observ...
Adverse reactions observed in KEYNOTE-407 were similar to those observed in KEYNOTE-189 with the exception that increased incidences of alopecia (47% vs 36%) and peripheral neuropathy (31% vs 25%) were observed in the KEYTRUDA and ...
The estimated time from reached clinically quiescent criteria to the first flare of disease (the clinically quiescent phase) was 28.30±3.07 months. In uni-variable analysis, age at SLE diagnosis ≥30 years married patients, non-alopecia at presentation, continuing anti-malarial drug therapy after ...
The most common adverse reactions (all grades ≥20%) were fatigue (70%), nausea (67%), alopecia (61%), rash (52%), constipation (42%), diarrhea and peripheral neuropathy (41% each), stomatitis (34...